Dopamine Stabilized in Ultra-nanoreservoirs for Controlled Delivery in Parkinson's Disease

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2025 Feb 12

PMID 39935342

Authors

Francisco J Padilla-Godinez

Tessy Lopez-Goerne

Evelyn Y Calvillo-Munoz

Mayra Angelica Alvarez-Lemus

Juan Navarrete-Bolanos

Omar Collazo-Navarrete

Obed R Lora-Marin

Maria-Del-Carmen Cardenas-Aguayo

Myrian Velasco

Magdalena Guerra-Crespo

Affiliations

Soon will be listed here.

Abstract

Aims: Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to impaired dopamine (DA) signaling and motor control. Intermittent dosing of current DA precursors results in side effects, prompting research into controlled drug release mechanisms for sustained and targeted delivery of DA.

Materials & Methods: In this work, we stabilized DA within a nanostructured silicate matrix (nanoreservoir) using the sol-gel method. We examined the physicochemical properties, kinetics of drug release, and biocompatibility in dopaminergic neurons and fibroblasts.

Results: The optimized synthesis method allowed for the stabilization of DA by preventing its oxidation. The physicochemical and controlled release analysis showed a direct relationship between the mesoporous structure, interaction of the DA with the matrix, and the release kinetics followed, proving the possibility to modify the rate of release by adjusting the synthesis parameters. Furthermore, the nanoreservoirs were biocompatible with dopaminergic neurons and fibroblasts

Conclusions: The research sets the stage for potential evaluations and new strategies for managing PD, offering hope for improved treatments based on DA and not derivatives.

References

Pifl C, Hornykiewicz O . Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem Int. 2006; 49(5):519-24. DOI: 10.1016/j.neuint.2006.03.013. View

Lopez T, Bata-Garcia J, Esquivel D, Ortiz-Islas E, Gonzalez R, Ascencio J . Treatment of Parkinson's disease: nanostructured sol-gel silica-dopamine reservoirs for controlled drug release in the central nervous system. Int J Nanomedicine. 2011; 6:19-31. PMC: 3025590. DOI: 10.2147/IJN.S13223. View

Simon D, Tanner C, Brundin P . Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2019; 36(1):1-12. PMC: 6905381. DOI: 10.1016/j.cger.2019.08.002. View

Barreto W, Barreto S, Ando R, Santos P, DiMauro E, Jorge T . Raman, IR, UV-vis and EPR characterization of two copper dioxolene complexes derived from L-dopa and dopamine. Spectrochim Acta A Mol Biomol Spectrosc. 2008; 71(4):1419-24. DOI: 10.1016/j.saa.2008.04.014. View

Bautista E, Zarco N, Aguirre-Pineda N, Lara-Lozano M, Vergara P, Gonzalez-Barrios J . Expression of Gas1 in Mouse Brain: Release and Role in Neuronal Differentiation. Cell Mol Neurobiol. 2017; 38(4):841-859. PMC: 11481942. DOI: 10.1007/s10571-017-0559-0. View

Padilla-Godinez F, Ruiz-Ortega L, Guerra-Crespo M . Nanomedicine in the Face of Parkinson's Disease: From Drug Delivery Systems to Nanozymes. Cells. 2022; 11(21). PMC: 9657131. DOI: 10.3390/cells11213445. View

Meskinis S, Vasiliauskas A, Andrulevicius M, Peckus D, Tamulevicius S, Viskontas K . Diamond Like Carbon Films Containing Si: Structure and Nonlinear Optical Properties. Materials (Basel). 2020; 13(4). PMC: 7079637. DOI: 10.3390/ma13041003. View

Li H, Xi J, Donaghue A, Keum J, Zhao Y, An K . Synthesis and catalytic performance of polydopamine supported metal nanoparticles. Sci Rep. 2020; 10(1):10416. PMC: 7319955. DOI: 10.1038/s41598-020-67458-9. View

Bernheimer H, Hornykiewicz O . [Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism]. Klin Wochenschr. 1965; 43(13):711-5. DOI: 10.1007/BF01707066. View

10.

Liu H, Zhu X, Weng E . Intracellular dopamine oxidation mediates rotenone-induced apoptosis in PC12 cells. Acta Pharmacol Sin. 2005; 26(1):17-26. DOI: 10.1111/j.1745-7254.2005.00003.x. View

11.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

12.

Xicoy H, Wieringa B, Martens G . The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Mol Neurodegener. 2017; 12(1):10. PMC: 5259880. DOI: 10.1186/s13024-017-0149-0. View

13.

Lippach A, Kramer R, Hansen M, Roos S, Stowe K, Stommel M . Synthesis and mechanical properties of organic-inorganic hybrid materials from lignin and polysiloxanes. ChemSusChem. 2012; 5(9):1778-86. DOI: 10.1002/cssc.201200095. View

14.

Miyazaki I, Asanuma M . Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama. 2008; 62(3):141-50. DOI: 10.18926/AMO/30942. View

15.

Supramaniam J, Adnan R, Mohd Kaus N, Bushra R . Magnetic nanocellulose alginate hydrogel beads as potential drug delivery system. Int J Biol Macromol. 2018; 118(Pt A):640-648. DOI: 10.1016/j.ijbiomac.2018.06.043. View

16.

Clogston J, Patri A . Zeta potential measurement. Methods Mol Biol. 2010; 697:63-70. DOI: 10.1007/978-1-60327-198-1_6. View

17.

Lockman P, Mumper R, Khan M, Allen D . Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 2002; 28(1):1-13. DOI: 10.1081/ddc-120001481. View

18.

Singh N, Pillay V, Choonara Y . Advances in the treatment of Parkinson's disease. Prog Neurobiol. 2007; 81(1):29-44. DOI: 10.1016/j.pneurobio.2006.11.009. View

19.

Groger A, Kolb R, Schafer R, Klose U . Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. PLoS One. 2014; 9(1):e84081. PMC: 3885536. DOI: 10.1371/journal.pone.0084081. View

20.

Pahuja R, Seth K, Shukla A, Shukla R, Bhatnagar P, Chauhan L . Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. ACS Nano. 2015; 9(5):4850-71. DOI: 10.1021/nn506408v. View